VIRALYTICS
Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia. Oncolytic virotherapy makes use of the cancer destroying capabilities of a range of benign viruses. The potential of oncolytic virotherapy is the ability to treat cancers more effectively and with minimum side-effects.
VIRALYTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.viralytics.com
Total Employee:
11+
Status:
Active
Contact:
+61 2 9988 4000
Email Addresses:
[email protected]
Total Funding:
27 M USD
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Aeris Environmental
Aeris Environmental Limited is listed on the Australian Stock Exchange (ASX:AEI) and has been built on decades of pioneering research.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Founder
Stock Details
Official Site Inspections
http://www.viralytics.com
- Host name: ec2-54-163-215-126.compute-1.amazonaws.com
- IP address: 54.163.215.126
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Viralytics"
Viralytics - Wikipedia
Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted … See moreSee details»
Viralytics - Crunchbase Company Profile & Funding
Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers …See details»
Merck and Viralytics Announce Acquisition Agreement, Expanding …
Feb 21, 2018 · Proposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK ® , Supporting Merck’s Strategy to Broaden Its Pipeline with the …See details»
Viralytics Company Profile 2024: Valuation, Investors
Developer of oncology therapeutics technologies and products designed to improve cancer immunotherapy. The company's products include anti-cancer therapeutic products, drugs, treatments and chemo-therapies, enabling cancer …See details»
Viralytics Company Profile - Office Locations, Competitors ... - Craft
Jun 11, 2018 · See insights on Viralytics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
UON biotech firm sells for $502 milion - HMRI - hmri.org.au
Feb 22, 2018 · In what is now one of the biggest biotech sales in Australian history, Viralytics – a virotherapy firm co-founded by the University of Newcastle and lead researcher Associate …See details»
Immunotherapy arms race latest: Merck buys Viralytics for $394m
Nov 10, 2024 · Merck & Co is to acquire Australian biotech Viralytics for $394 million, adding a virus-based immunotherapy to its R&D pipeline. The acquisition, hot on the heels of BMS' $1.8 …See details»
Merck Signs Definitive Agreement To Acquire Viralytics For $394M
Feb 21, 2018 · Merck and Viralytics announce acquisition agreement, expanding Merck’s leading immuno-oncology pipeline.See details»
Merck to buy virus-based cancer drug firm Viralytics for $394 million
Feb 21, 2018 · Merck will pay 1.75 Australian dollars per share for the Sydney-based biotech company, which uses viruses to infect and kill cancer cells. The idea is to cause cancer cells …See details»
Merck signs its acquisition agreement with Viralytics to Increase its ...
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company’s lead investigational product, CAVATAK®, is currently being studied in clinical trials …See details»
Merck buys virus maker to flesh out I/O pipeline - BioPharma Dive
Feb 21, 2018 · Merck & Co. plans to grow its immuno-oncology pipeline through a nearly $400 million acquisition of Australian drugmaker Viralytics Ltd. Viralytics uses oncolytic viruses to …See details»
Merck inks $394M takeover of oncolytic virus play Viralytics
Feb 21, 2018 · Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in …See details»
Merck snaps up local biotech Viralytics for $500m - Financial Review
Feb 22, 2018 · Global pharmaceutical giant Merck & Co has snapped up Australia's Viralytics in a $502 million deal to secure its immunotherapy cancer drug.See details»
Viralytics to be acquired for $502 million - Biotech - BiotechDispatch
Feb 22, 2018 · US-based global pharmaceutical company MSD has announced it will acquire Australian-based biotechnology company Viralytics (ASX:VLA) in a deal that values the …See details»
New biotech venture going viral in battle against cancer
Jan 22, 2020 · The scientific team behind Viralytics, a Hunter-based biotech firm bought in 2018 by Merck for a record $502 million, is reuniting for a new private venture aiming to develop …See details»
Biotech team going viral to combat cancer - HMRI - hmri.org.au
Jan 19, 2020 · The scientific team behind Viralytics, a Hunter-based biotech firm bought in 2018 by Merck for a record $502 million, is reuniting for a new private venture aiming to develop …See details»
Merck ditches Cavatak more than 4 years after buying Viralytics
Oct 27, 2022 · Merck & Co. is bidding adieu to the oncolytic virus acquired from its 2018 purchase of Viralytics, with the pipeline change disclosed weeks after the Big Pharma hitched its wagon …See details»
Viralytics Limited - Financial Review
ImmVirX has raised $22 million from Acorn Capital to fund its phase one human trials for a new cancer treatment using a virus to kill tumours. The team behind ex-ASX listed biotech …See details»
Viralytics band back together for ImmVirX cancer start-up
May 12, 2021 · The team behind immuno-oncology success story Viralytics is back together and having another crack at developing a therapy harnessing a person’s own immune system to …See details»
TikTok Shop Analytics: Find Viral Products & Top Creators Insights
Explore TikTok Shop Analytics with our tool to discover viral products, creators, and shoppable videos. Trusted by TikTok Shop sellers for comprehensive sales data research.See details»